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Different measures may be used to describe how often
disease (or another health event) occurs in a population.
Incidence expresses the development of new cases and is
mostly used against the background of prevention, to assess
disease etiology or to determine the risk factors of disease.
Depending on the specific study question, incidence may be
reported as risk or as incidence rate. This paper discusses that
it is preferable to use incidence rate in case of a dynamic
population or in cases where the observation period is
sufficiently long for competing risks or loss to follow-up to
play a significant role. Prevalence is the number of existing
cases, which is affected by both the number of incident cases
and the length of disease time. It reflects the burden of
disease on a population that may, among others, be
measured in terms of costs or morbidity. Knowledge about
this burden can be used for the planning of health-care
facilities. This paper discusses the different measures of
disease occurrence using a number of examples taken from
the nephrology literature.
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Epidemiology is the study of the occurrence of disease. In this
case ‘disease’ should be interpreted quite broadly, as
epidemiology studies many types of health outcomes or
events. The Centers for Disease Control and Prevention
therefore use a wider definition like ‘the study of the
distribution and determinants of health-related states or
events in specified populations, and the application of this
study to the control of health problems’.1 The type of
measure of disease occurrence to be used for analysis depends
on the purpose of a study.
If we are performing a study against the background of
prevention and we aim to assess the etiology of a disease or
event and determine its risk factors, we are interested in the
development of new cases of that disease over a period of
follow-up, the so-called incidence. Should we, on the other
hand, wish to know the burden of disease on a population
because we need this for the planning of health-care facilities
it is much more useful to know the number of existing cases
that is expressed by the prevalence of disease.
INCIDENCE
Two measures of disease occurrence deal with new cases: risk
and incidence rate (for a definition of terms see Table 1). Risk
is a proportion; it is the ratio of the number of subjects
developing disease (or other health outcome) over a specific
period to the number of subjects followed:
Risk ¼ Number of subjects developing disease during a time period
Number of subjects followed for the time period
To quantify risk (synonyms: cumulative incidence, incidence
proportion), it is always necessary to define a time period to
which the risk applies. This can simply be illustrated with the
concept of risk of death. We as humans can be fairly certain
that the risk of death within 150 years is 100%, whereas the
risk of death within 1 day will usually be quite small.
Secondly, the concept of risk assumes that subjects are
followed for the entire time period. That such may not always
be the case is illustrated by example 1 that was taken from the
paper of Puliyanda et al.2
Example 1 – Risk
The paper of Puliyanda et al.2 describes a cohort of 3106
children during the first 2 years post-renal transplantation. One
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of the purposes of the study was to determine the risk of
hospitalization for bacterial infection in the first 2 years after
renal transplantation. One hundred and sixty-four children lost
their grafts in the first 6 months after transplantation. Six
hundred and eighty-seven patients were hospitalized for
bacterial infection.
In this example, what would be the risk of hospitalization
for bacterial infection in the first 2 years post-renal
transplantation? There were 3106 children ‘at risk’ at the
moment of transplantation. As 687 children developed
bacterial infection for which they needed to be admitted to
hospital the risk should, according to its definition, be
calculated as 687/3106¼ 22.1%. The problem was, however,
that 164 children lost their graft for another reason than
bacterial infection and were therefore not able anymore to
develop the event of interest. This example shows that there
are problems with the concept of risk as a measure of disease
occurrence. In general, such problems will occur if the
observation period is relatively long and study participants
may cease to be at risk for the event of interest, for example,
because they die from other causes or get lost to follow-up.3
One could consider the risk of death from other causes as
‘competing’ with the risk of the event of interest. Although,
intuitively, risk is relatively easy to interpret, in cases where
the observation period is sufficiently long for competing risks
or loss to follow-up to play a significant role, risk may be less
suitable as a measure of incidence.4 As explained in the next
paragraph, other circumstances where risk may not be the
preferred measure of disease occurrence include the use of
dynamic populations as populations at risk and in studies
where events can happen more than once in one individual.
Therefore, in many cases it is better to use incidence rate.
Incidence rate is the ratio of the number of subjects
developing disease (or other health outcome) to the time at
risk for disease:
Incidence rate ¼ Number of subjects developing disease
Total time at risk for the subjects followed
This formula shows that incidence rate differs from risk in
that the denominator includes a measure of time instead of a
number of subjects. In this perspective, incidence rate is an
instantaneous concept, like speed. A major advantage of
using incidence rate (synonyms: incidence density, hazard,
force of morbidity/mortality) compared to using risk is that
it is not required for every study subject to complete the
entire risk period, as only ‘time at risk’ is taken into account.
This property makes the incidence rate very useful in
dynamic populations, in cases where subjects may or may
not be at risk for the event of interest for particular periods of
time. Suppose we would be interested in the incidence rate of
peritonitis requiring hospitalization in continuous ambula-
tory peritoneal dialysis (CAPD) patients in 2004 and we
would have diagnosed a number of such peritonitis episodes
in 17 CAPD patients. We would then need to calculate the
total time at risk, that is, the total time on CAPD. Figure 1
shows that together these 17 patients were 144 patient-
months at risk. In this period, there were four of such
episodes. The incidence rate of peritonitis episodes requiring
hospitalization would therefore be 4/144¼ 0.028 per patient-
month or 4/12¼ 0.33 per patient-year.
Example 2 – Incidence rate
For the year 2005, Kramar and Oberbauer5 reported a number
of 374 renal transplants in an Austrian population of 8.1
million inhabitants. The incidence rate of renal transplantation
in Austria in that year was therefore 46 transplants per million
person-years or, as it is usually stated, per million population.
Another practical application of incidence rate is renal
transplant rate as shown in example 2. In order to be able to
compare transplant activity between countries, registries
divide annual transplant numbers by the number of country
inhabitants. For a dynamic population as the general
population, it is unfeasible to calculate the different times
at risk for different persons and then add them up. However,
under steady-state conditions persons dying in this general
population are being replaced by newborns and, therefore,
Table 1 | Definitons of terms
Concept Definition Formula
Incidence Risk
Incidence
rate
Prevalence Point
prevalence
Proportion of people in a
population having disease at
a particular point in time
Proportion of people in a
population having disease
over a period of time
Period
prevalence
Ratio of the number of cases
to the time at risk for disease
Probability of developing
disease No. of subjects developing disease during a time period 
No. of subjects developing disease
Total time at risk for the subjects followed
No. of subjects having disease at a particular point in time
No. of subjects with disease at the start of the period + no. of subjects developing
disease over the time period
Total no. of subjects in the population
Total no. of subjects in the population
No. of subjects followed for the time period 
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the population number can be taken as a proxy for the
number of person-years lived in the general population.
Another property of incidence rate is that, under steady-
state conditions in which rates do not change with time, it is
the reciprocal of the waiting time, that is, the average time
until an event occurs. If we go back to the example of the
incidence rate of peritonitis requiring hospitalization in
CAPD patients, we could easily calculate that the average
waiting time for a peritonitis requiring hospitalization to
occur in a CAPD patient is 1/0.33¼ 3 years.
One can imagine that when measured over short periods
of time, the risk and the incidence rate will be similar, as there
will be little loss to follow-up and competing risk will only
play a minor role. For this reason, in-hospital mortality for
acute renal failure is commonly expressed as a risk, whereas
mortality on dialysis for end-stage renal disease (ESRD) is
usually expressed as a rate. A further comparison of the
properties of risk and incidence rate is shown in Table 2.
PREVALENCE
Whereas incidence assesses the frequency of disease onset,
prevalence is a measure of disease status: it deals with existing
cases of disease. Prevalence is the proportion of people in a
population having disease:
Prevalence ¼ Number of subjects having disease at a particular point in time
Total number of subjects in the population
This definition of prevalence (synonym: prevalence propor-
tion) reflects so-called ‘point prevalence’ that is most
commonly used as the measure dealing with existing cases.
Sometimes, however, researchers make use of ‘period
prevalence’. This measure includes existing cases at the start
of the period plus the new cases that develop over the study
period, for example, 1 year. This total is then divided by the
total number of subjects in the population. Therefore,
suppose that out of the 80 patients in our dialysis center
there were 20 patients with ESRD due to glomerulonephritis
at the beginning of 2005 and that during this year there were
two new patients with the same condition taken into dialysis.
Then the point prevalence of ESRD due to glomerulone-
phritis at the beginning of 2005 was 20/80¼ 0.25, but the
period prevalence in the year 2005 was 22/80¼ 0.275.
Prevalence is affected by both the number of incident cases
and the length of disease time. Given a steady state and a low
prevalence, the prevalence equals the product of the incidence
rate and the mean duration of disease (Prevalence¼ Inci-
dence rateAverage disease duration). This is easily
illustrated by the examples of aortic hemorrhage and ESRD.
The first disease leads to rapid death resulting in a short
disease duration; and therefore, its prevalence in the general
population at any point in time will be extremely low. ESRD,
on the other hand, has a relatively low incidence rate, but in
comparison to aortic hemorrhage its survival is much higher,
at least in developed countries. As a consequence, its average
disease duration is much longer; and therefore, its prevalence
is much higher compared to that of aortic hemorrhage. In the
perspective of ESRD, this dependency of prevalence can
further be illustrated by the fact that an increase in prevalence
could be the result of a higher incidence of ESRD, of an
improved survival or be the consequence of both.
Prevalence is said to reflect the burden of disease in a
population. Burden can be measured in terms of costs, life
expectancy, morbidity, quality of life, or other indicators.
Knowledge of the burden of disease can help determine
where investment in health should be targeted. Knowing that
the average cost of dialysis patients per year within Medicare
was 66 650 US dollars per patient in 2004,6 multiplication by
the number of prevalent patients will yield the total costs for
dialysis patients within this part of the US health-care system.
Example 3 is an illustration of how cost calculation per
patient may be used to determine the economic burden of
specific medication in dialysis patients.
Example 3 – Prevalence
Lorenzo et al.7 did a study among 1312 hemodialysis patients
from six centers in Spain, which was estimated to represent
almost 10% of all hemodialysis patients in Spain. They
performed a cost analysis to evaluate the economic burden of
Table 2 | A comparison of properties of risk and incidence
rate (adapted from Rothman4)
Property
Range
Units
Interpretation Probability Reciprocal of waiting time
None 1/time
0−1 (0−100%) 0− infinity
Risk Incidence rate
Patients
Newly started PD
Newly started PD
Newly started PD
Newly started PD
Died
Died
Transfer to HD
Transfer to HD
Transfer from HD
Patient months
1
2
2
2
2
3
3
4
4
4
4
5
5
5
6
6
6
7
7
7
8
8
8
9
9
10
10
10
11
11
12
12
12
12
12
12
12
12
12
12 144
13
14
15
16
17
0
1 January 2004 31 December 2004Months
Peritonitis episode
1
Figure 1 | Time at risk for peritonitis requiring hospitalization in
17 CAPD patients.
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mineral regulating therapy in this patient group. It turned out
that on average the cost of this specific therapy was 1.68 Euro
per patient per day.
Had the sample in the study of Lorenzo et al. indeed
represented almost 10% of the hemodialysis patients in Spain
and had it been a representative sample, the costs of mineral
regulating therapy for this patient group in Spain could have
been estimated at slightly more than 8 million Euro per year.
MEASURES OF EFFECT
Measures of disease occurrence may also be used to study the
risk factors or causes of disease. To assess the effect of a risk
factor, comparisons are made between, for example, disease
frequency in people who have been exposed to that risk factor
and disease frequency in those who have not been exposed to
that risk factor. To express the size of such effects, one uses
either differences between measures of disease occurrence or
ratios of those measures. A later paper in this series will
address these different measures of effect.
SUPPLEMENTARY MATERIAL
The supplementary material is available at www.kidney-
international.org.
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